

References

I-245

1. Saphnelo™ (Anifrolumab), injection for intravenous use [package insert]. Pharma company. Wilmington, DE. Revised 12/2023.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Anifrolumab.
3. Micromedex DrugDex Compendium®. 2024. Anifrolumab.
4. Anifrolumab-fnia In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated September 27, 2023.
5. Furie R, Morand EF, Askanase AD, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. *Lupus*. 2021;30(8):1254-1263.
6. Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. *Arthritis Rheumatol*. 2021;73(5):816-825.
7. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. *N Engl J Med*. 2020;382(3):211-221
8. Kalunian KC, Furie R, Morand EF, et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2023;75(2):253-265.